|
|
|
|
||
Re: PNH Treatment Market Size Worth $5.8 Billion by 2025Mentioned in the "free" portion of that report : C5 inhibitors ALXN1210 (approved), Coversin, RA101495, and APL-2, a C3 inhibitor. The C5 class tends to have SAEs in the 15% range, while APL-2 from Apellis has shown a 17% SAE level. BCRX may have a big leg up here. |
return to message board, top of board |